Omvoh vs Stelara for Crohn's Disease: Key Differences

Omvoh and Stelara are two IL-23 pathway biologics for moderate-to-severe Crohn's disease, but they target the pathway at different points. Stelara blocks both IL-12 and IL-23 through the shared p40 subunit. Omvoh selectively blocks only IL-23 through its p19 subunit. The scientific rationale behind p19 selectivity is that IL-23 is the dominant driver of Crohn's inflammation while IL-12 plays broader immune roles that may not need blocking. Omvoh's VIVID-1 trial directly compared mirikizumab with ustekinumab as an active comparator, giving patients meaningful head-to-head data. This guide walks through the omvoh vs stelara crohn's decision.

IL-23 p19 vs IL-12/23 p40

Stelara (ustekinumab) binds the p40 subunit shared by IL-12 and IL-23, blocking both cytokines. Omvoh (mirikizumab) binds the p19 subunit unique to IL-23, blocking only that cytokine. IL-23 is a dominant driver of the Th17 pathway that fuels Crohn's inflammation, while IL-12 plays roles in normal immune function. The mirikizumab vs ustekinumab rationale is that blocking only IL-23 delivers the Crohn's-relevant anti-inflammatory effect while preserving IL-12-mediated immune surveillance. Whether this theoretical advantage produces measurable clinical differences was partially tested in VIVID-1, where mirikizumab showed comparable efficacy to ustekinumab with strong safety data.

VIVID-1 Trial Comparison

VIVID-1 was a pivotal phase 3 trial of mirikizumab in Crohn's that included ustekinumab as an active comparator arm. The trial randomized biologic-naive and biologic-experienced patients to mirikizumab, ustekinumab, or placebo. Mirikizumab achieved its primary endpoints against placebo, and the active comparator design showed broadly similar efficacy between mirikizumab and ustekinumab on clinical response and endoscopic improvement measures. Two-year extension data has supported durable response on mirikizumab. While the trial was not powered as a superiority comparison between the two active drugs, the data provides useful direct evidence that Omvoh performs similarly to Stelara in Crohn's.

Onset of Action

Both drugs produce clinically meaningful response by week 12, consistent with IL-23 pathway biologics. Stelara's single weight-based IV induction dose allows patients to transition quickly to SC maintenance. Omvoh uses three IV induction doses at weeks 0, 4, and 8 before transitioning to SC maintenance. For Crohn's patients comparing early response timelines, both drugs are slower than anti-TNFs but faster than Entyvio. For patients with severe, active disease who need rapid control, neither IL-23 pathway biologic is the fastest option. For patients in less acute states or those prioritizing safety, both drugs offer reasonable response trajectories.

Safety and Tolerability

Both drugs have favorable safety profiles relative to anti-TNFs. Stelara's long-term IBD experience, spanning more than a decade, shows low rates of serious infection and good tolerability. Omvoh's safety data from VIVID-1 and the broader LUCENT UC program has been consistent with the class, showing low infection rates and no unexpected safety signals. For omvoh vs stelara effectiveness and tolerability, the two drugs look broadly similar in clinical trial data. Both carry boxed warnings related to serious infections, both require TB and hepatitis B screening before starting, and both are typically used as monotherapy without combination immunomodulators.

Administration and Dosing

Stelara uses a single weight-based IV induction dose at week 0, then transitions to 90 mg SC every 8 weeks. Omvoh for Crohn's uses IV induction at weeks 0, 4, and 8 (900 mg per infusion), followed by SC maintenance of 300 mg every 4 weeks. For Crohn's patients comparing induction burden, Stelara's single IV dose is meaningfully less committing than Omvoh's three IV doses. For long-term maintenance frequency, Stelara's every-8-week SC dosing is less frequent than Omvoh's every-4-weeks schedule. Patients who strongly prefer fewer injections over the long run may lean toward Stelara. Those willing to accept more frequent SC dosing for p19 selectivity may lean toward Omvoh.

Cost and Access

Stelara now faces biosimilar competition in the US, with several interchangeable ustekinumab biosimilars reaching market starting in 2025. This has lowered acquisition costs and shifted formulary preferences toward ustekinumab biosimilars in many plans. Omvoh has no biosimilar and is priced as a branded biologic. For Crohn's patients where insurance favors a ustekinumab biosimilar, Stelara (or its biosimilar) may be the most accessible option at the lowest cost. For patients whose plans cover Omvoh without major cost differences, the p19 selectivity and VIVID-1 data may justify the choice. Manufacturer copay assistance programs are available for Omvoh to help commercially insured patients bridge cost gaps.

Choosing With Your GI

For a Crohn's patient deciding between Omvoh and Stelara, VIVID-1 provides some direct evidence that both drugs perform similarly in efficacy. Stelara offers a single-dose IV induction, less frequent SC maintenance, an extensive long-term safety record, and biosimilar availability that often lowers cost. Omvoh offers the theoretical benefit of p19 selectivity, strong two-year efficacy data, and a newer drug profile. Ask your GI whether there is a preferred option based on your specific disease pattern, prior biologic exposure, and insurance coverage. A log of stool frequency, urgency, abdominal pain, and any new symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.